Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Restasis in PROSE devices for Ocular Surface Disease
NCT04918823Phase 2Completed
- Sponsor
- BostonSight
- Start
- Jul 2021
- Primary completion
- Apr 2023
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclosporine in ocular surface disease (OSD), sponsored by BostonSight. Primary endpoints: Ocular Surface Disease Index Score Change at 1 month, Corneal Staining at 1 month and 5 more. Started Jul 2021; status: completed.
02
Drugs
cyclosporine
03
Conditions
ocular surface disease (OSD)
Beyond the preview
Go deeper on NCT04918823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04918823.